Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inhibikase Therapeutics, Inc. (IKT)
USD2.08
+0.02 (+0.97%)
US NASDAQ Healthcare Medical - Pharmaceuticals
Address
1000 N. West Street 19801
Wilmington, DE, US
Wilmington, DE, US
CEO
Mark T. Iwicki
Website
inhibikase.com
IPO
2020-12-23
CIK 1750149 ISIN US45719W2052
Description
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.08
+0.02 (+0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
838.6K
Beta
0.97
Float Shares
41.65M
Free Float %
58.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.42% | -4.48% | +12.94% | +17.07% | +18.52% | -6.34% | -12.33% | -47.83% | -94.01% | -96.77% | -96.77% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Hold
Price Targets & DCF
Current price
2.08
Low
4.00
+92.3%
Consensus
4.00
+92.3%
Median
4.00
+92.3%
High
4.00
+92.3%
DCF (Unlevered)
1.41
-32.4%
DCF (Levered)
1.42
-31.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
4.00
+92.3%
|
| All Time | 3 |
5.67
+172.6%
|
Quality scores
Altman Z-Score
13.16
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+57.8% ★ Q1'26: +33.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+41.7% Q1'26: +92.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.10M
est: 3.40M (-8.8%)
|
123.4K
est: 100.0K (+23.4%)
|
260.5K
est: 79.6K (+227.4%)
|
—
|
—
|
375.0K
362.5K – 387.5K
|
500.0K
500.0K – 500.0K
+33.3% YoY
|
36.74M
36.74M – 36.74M
+7,247.4% YoY
|
164.94M
164.94M – 164.94M
+349.0% YoY
|
290.67M
290.67M – 290.67M
+76.2% YoY
|
| EBITDA |
—
est: -680.0K (+100.0%)
|
-18.05M
est: -20.0K (-90,141.7%)
|
-19.91M
|
-27.49M
|
-45.89M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-14.77M
est: -2.04M (-623.8%)
|
-18.05M
est: -60.0K (-29,990.3%)
|
-20.09M
est: -15.9K (-126,147.7%)
|
-27.52M
|
-45.95M
|
-75.0K
-77.5K – -72.5K
|
-100.0K
-100.0K – -100.0K
-33.3% YoY
|
-7.35M
-7.35M – -7.35M
-7,247.5% YoY
|
-32.99M
-32.99M – -32.99M
-349.0% YoY
|
-58.13M
-58.13M – -58.13M
-76.2% YoY
|
| Net Income |
-14.79M
est: -324.62M (+95.4%)
|
-18.05M
est: -307.97M (+94.1%)
|
-19.03M
est: -308.34M (+93.8%)
|
-27.52M
est: -62.33M (+55.9%)
|
-48.26M
est: -48.26M (+0.0%)
|
-45.70M
-54.24M – -37.17M
+5.3% YoY
|
-46.71M
-56.82M – -36.59M
-2.2% YoY
|
-36.11M
-44.67M – -27.56M
+22.7% YoY
|
11.31M
11.31M – 11.31M
+131.3% YoY
|
59.48M
59.48M – 59.48M
+426.1% YoY
|
| SGA |
—
est: 52.46M (-100.0%)
|
6.21M
est: 1.54M (+302.5%)
|
6.73M
est: 1.24M (+441.3%)
|
11.38M
|
23.56M
|
5.86M
5.67M – 6.06M
|
7.82M
7.82M – 7.82M
+33.3% YoY
|
574.22M
574.22M – 574.22M
+7,247.4% YoY
|
2.58B
2.58B – 2.58B
+349.0% YoY
|
4.54B
4.54B – 4.54B
+76.2% YoY
|
| EPS |
-4.88
est: -4.68 (-4.3%)
|
-4.26
est: -4.44 (+4.1%)
|
-3.57
est: -3.14 (-13.8%)
|
-1.16
est: -0.90 (-28.4%)
|
-0.49
est: -0.50 (+1.9%)
|
-0.47
-0.55 – -0.38
+5.9% YoY
|
-0.48
-0.58 – -0.37
-2.1% YoY
|
-0.39
-0.45 – -0.28
+19.4% YoY
|
0.12
0.12 – 0.12
+129.7% YoY
|
0.61
0.61 – 0.61
+426.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-35.74M
OE per share TTM
-0.33
Owner's Yield
-10.80%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
19.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
33.73M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Frank M. Sands | 10.95M | 16.30% | — | 10.95M | — | — | IN | Cayman Islands | 2024-10-25 | ↗ |
| 2 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10.95M | 16.30% | — | 10.95M | — | 10.95M | PN | Cayman Islands | 2024-10-25 | ↗ |
| 3 | Sands Capital Ventures, LLC | 10.95M | 16.30% | — | 10.95M | — | 10.95M | OO | Cayman Islands | 2024-10-25 | ↗ |
| 4 | Soleus PE GP III, LLC | 7.23M | 9.99% | — | 7.23M | — | 7.23M | OO | Delaware | 2024-10-28 | ↗ |
| 5 | Soleus Private Equity Fund III, L.P. | 7.23M | 9.99% | — | 7.23M | — | 7.23M | PN | Delaware | 2024-10-28 | ↗ |
| 6 | Soleus Private Equity GP III, LLC | 7.23M | 9.99% | — | 7.23M | — | 7.23M | OO | Delaware | 2024-10-28 | ↗ |
| 7 | Soleus Capital Group, LLC | 6.98M | 9.99% | — | 6.98M | — | 6.98M | OO | Delaware | 2024-10-28 | ↗ |
| 8 | Soleus Capital Master Fund, L.P. | 6.98M | 9.99% | — | 6.98M | — | 6.98M | FI | Delaware | 2024-10-28 | ↗ |
| 9 | Soleus Capital, LLC | 6.98M | 9.99% | — | 6.98M | — | 6.98M | OO | Delaware | 2024-10-28 | ↗ |
| 10 | Capital LP | 6.81M | 9.99% | — | 6.81M | — | 6.81M | IA | Delaware, USA | 2024-10-17 | ↗ |
| 11 | Capital Master LP | 6.81M | 9.99% | — | 6.81M | — | 6.81M | OO | Delaware, USA | 2024-10-17 | ↗ |
| 12 | Joseph Edelman | 6.80M | 9.99% | — | 6.80M | — | 6.80M | IN | Delaware | 2024-10-22 | ↗ |
| 13 | Perceptive Advisors LLC | 6.80M | 9.99% | — | 6.80M | — | 6.80M | IA | Delaware | 2024-10-22 | ↗ |
| 14 | Perceptive Life Sciences Master Fund, Ltd. | 6.80M | 9.99% | — | 6.80M | — | 6.80M | CO | Delaware | 2024-10-22 | ↗ |
| 15 | Guy Levy | 6.76M | 9.99% | — | 6.76M | — | 6.76M | IN | Delaware | 2024-10-28 | ↗ |
| 16 | Soleus Capital Management, L.P. | 6.76M | 9.99% | — | 6.76M | — | 6.76M | PN | Delaware | 2024-10-28 | ↗ |
| 17 | Fairmount Funds Management LLC | 6.62M | 9.90% | — | 6.62M | — | — | IA | Delaware | 2024-10-17 | ↗ |
| 18 | Fairmount Healthcare Fund II L.P. | 6.62M | 9.90% | — | 6.62M | — | — | PN | Delaware | 2024-10-17 | ↗ |
| 19 | Peter Harwin | 6.62M | 9.90% | — | 6.62M | — | — | HC, IN | Delaware | 2024-10-17 | ↗ |
| 20 | Tomas Kiselak | 6.62M | 9.90% | — | 6.62M | — | — | HC, IN | Delaware | 2024-10-17 | ↗ |
| 21 | Holdings LLC | 5.84M | 8.69% | — | 5.84M | — | 5.84M | OO | DELAWARE | 2024-10-28 | ↗ |
| 22 | LLC | 5.84M | 8.69% | — | 5.84M | — | 5.84M | OO | DELAWARE | 2024-10-28 | ↗ |
| 23 | Armistice Capital, LLC | 758.9K | 9.99% | — | 758.9K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 24 | Steven Boyd | 758.9K | 9.99% | — | 758.9K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 25 | Point72 Asset Management, L.P. | 625.0K | 8.40% | — | 625.0K | — | — | PN | Delaware | 2024-10-10 | ↗ |
| 26 | Steven A. Cohen | 625.0K | 8.40% | — | 625.0K | — | — | IN | Delaware | 2024-10-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-45 vs prev Q
New positions
14
Closed positions
59
Increased
22
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SANDS CAPITAL VENTURES, LLC | 13.02M +2.1M (+18.9%) | 26.69M +8.9M (+50.5%) | 14.46% +2.292 pp | 5.15% +1.261 pp | USD3.06 -33.0% | 5 qtrs — |
| 2 | SOLEUS CAPITAL MANAGEMENT, L.P. | 10.88M +4.6M (+71.9%) | 22.29M +12.0M (+117.6%) | 12.08% +5.050 pp | 0.82% +0.307 pp | USD2.75 -25.5% | 5 qtrs — |
| 3 | FAIRMOUNT FUNDS MANAGEMENT LLC | 8.63M +2.5M (+40.8%) | 17.68M +7.8M (+78.2%) | 9.58% +2.773 pp | 1.35% +0.453 pp | USD2.90 -29.3% | 5 qtrs — |
| 4 | ADAR1 CAPITAL MANAGEMENT, LLC | 8.06M +2.8M (+53.7%) | 16.53M +8.0M (+94.5%) | 8.95% +3.125 pp | 1.21% +0.416 pp | USD2.80 -26.8% | 5 qtrs — |
| 5 | BLACKSTONE INC. | 5.94M +3.3M (+125.1%) | 12.17M +7.9M (+184.8%) | 6.59% +3.663 pp | 0.05% +0.031 pp | USD2.46 -16.7% | 5 qtrs — |
| 6 | SIREN, L.L.C. | 5.85M +5.9M (+100.0%) | 11.99M +12.0M (+100.0%) | 6.50% +6.496 pp | 0.36% +0.358 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 7 | PERCEPTIVE ADVISORS LLC | 5.42M +— (+0.0%) | 11.11M +2.3M (+26.5%) | 6.02% -0.003 pp | 0.20% -0.056 pp | USD3.25 -36.9% | 5 qtrs — |
| 8 | COMMODORE CAPITAL LP | 5.40M +— (+0.0%) | 11.06M +2.3M (+26.5%) | 5.99% -0.003 pp | 0.74% +0.310 pp | USD3.24 -36.7% | 5 qtrs — |
| 9 | VANGUARD GROUP INC | 4.56M +1.3M (+39.3%) | 9.35M +4.0M (+76.2%) | 5.06% +1.426 pp | 0.00% +0.000 pp | USD2.78 -26.3% | 11 qtrs — |
| 10 | NANTAHALA CAPITAL MANAGEMENT, LLC | 3.93M +1.7M (+79.4%) | 8.06M +4.5M (+127.0%) | 4.36% +1.930 pp | 0.27% +0.143 pp | USD2.72 -24.6% | 5 qtrs — |
| 11 | SATURN V CAPITAL MANAGEMENT LLC | 3.86M +3.9M (+100.0%) | 7.91M +7.9M (+100.0%) | 4.28% +4.283 pp | 1.45% +1.451 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 12 | BLACKROCK, INC. | 3.31M +230.4K (+7.5%) | 6.78M +1.8M (+36.0%) | 3.67% +0.254 pp | 0.00% +0.000 pp | USD2.06 -0.5% | 5 qtrs — |
| 13 | STONEPINE CAPITAL MANAGEMENT, LLC | 2.35M +1.6M (+219.5%) | 4.81M +3.6M (+304.3%) | 2.61% +1.791 pp | 3.51% +2.546 pp | USD2.42 -15.3% | 5 qtrs — |
| 14 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.75M +1.8M (+100.0%) | 3.59M +3.6M (+100.0%) | 1.94% +1.943 pp | 0.18% +0.178 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 15 | AMERIPRISE FINANCIAL INC | 1.38M +1.4M (+100.0%) | 2.82M +2.8M (+100.0%) | 1.53% +1.529 pp | 0.00% +0.001 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 16 | CITADEL ADVISORS LLC | 1.24M +1.2M (+1,635.2%) | 2.55M +2.4M (+2,095.8%) | 1.38% +1.301 pp | 0.00% +0.000 pp | USD2.03 +1.0% | 2 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 1.13M +15.7K (+1.4%) | 2.31M +510.5K (+28.3%) | 1.25% +0.017 pp | 0.00% +0.000 pp | USD2.23 -8.1% | 11 qtrs — |
| 18 | EXOME ASSET MANAGEMENT LLC | 600.0K +600.0K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.67% +0.666 pp | 0.59% +0.588 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 19 | STATE STREET CORP | 554.8K +47.1K (+9.3%) | 1.14M +314.9K (+38.3%) | 0.62% +0.052 pp | 0.00% +0.000 pp | USD1.96 +4.6% | 11 qtrs — |
| 20 | — | 533.6K +533.6K (+100.0%) | 1.09M +1.1M (+100.0%) | 0.59% +0.593 pp | 0.83% +0.832 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 21 | NORTHERN TRUST CORP | 322.7K -51.6K (-13.8%) | 661.6K +55.2K (+9.1%) | 0.36% -0.058 pp | 0.00% +0.000 pp | USD2.16 -5.1% | 5 qtrs — |
| 22 | MILLENNIUM MANAGEMENT LLC | 169.9K +169.9K (+100.0%) | 348.2K +348.2K (+100.0%) | 0.19% +0.189 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 23 | BLAIR WILLIAM & CO/IL | 153.0K +— (+0.0%) | 313.6K +65.8K (+26.5%) | 0.17% 0.000 pp | 0.00% +0.000 pp | USD1.78 +15.2% | 11 qtrs — |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 152.3K +— (+0.0%) | 312.2K +65.5K (+26.5%) | 0.17% 0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 25 | BANK OF NEW YORK MELLON CORP | 137.5K -1.2K (-0.9%) | 281.8K +57.2K (+25.5%) | 0.15% -0.001 pp | 0.00% +0.000 pp | USD1.94 +5.7% | 3 qtrs — |
| 26 | JANE STREET GROUP, LLC | 116.0K +116.0K (+100.0%) | 237.8K +237.8K (+100.0%) | 0.13% +0.129 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 27 | BARCLAYS PLC | 94.8K +9.2K (+10.8%) | 194.3K +55.7K (+40.2%) | 0.11% +0.010 pp | 0.00% +0.000 pp | USD2.85 -28.1% | 5 qtrs — |
| 28 | UBS GROUP AG | 94.5K -41.7K (-30.6%) | 193.8K -27.0K (-12.2%) | 0.11% -0.046 pp | 0.00% +0.000 pp | USD1.91 +7.3% | 10 qtrs — |
| 29 | PERSISTENT ASSET PARTNERS LTD | 93.4K +93.4K (+100.0%) | 191.5K +191.5K (+100.0%) | 0.10% +0.104 pp | 0.09% +0.086 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 30 | GOLDMAN SACHS GROUP INC | 85.3K +74.5K (+694.3%) | 174.8K +157.4K (+905.1%) | 0.09% +0.083 pp | 0.00% +0.000 pp | USD2.00 +2.5% | 5 qtrs — |
| 31 | MORGAN STANLEY | 79.7K +23.7K (+42.2%) | 163.3K +72.6K (+80.0%) | 0.09% +0.026 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 11 qtrs — |
| 32 | NUVEEN, LLC | 78.7K +— (+0.0%) | 161.3K +33.8K (+26.5%) | 0.09% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 33 | WELLS FARGO & COMPANY/MN | 67.8K +22.1K (+48.3%) | 139.1K +64.9K (+87.6%) | 0.08% +0.025 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 11 qtrs — |
| 34 | FMR LLC | 57.4K -48.4K (-45.8%) | 117.6K -53.7K (-31.4%) | 0.06% -0.054 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 35 | DEUTSCHE BANK AG\ | 54.9K -25.6K (-31.8%) | 112.6K -17.8K (-13.7%) | 0.06% -0.029 pp | 0.00% +0.000 pp | USD1.62 +26.5% | 2 qtrs — |
| 36 | NEW YORK STATE COMMON RETIREMENT FUND | 47.9K +— (+0.0%) | 98.2K +20.6K (+26.5%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 37 | RHUMBLINE ADVISERS | 47.2K -10.4K (-18.1%) | 96.7K +3.5K (+3.7%) | 0.05% -0.012 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 46.4K +29.3K (+171.4%) | 95.1K +67.4K (+243.4%) | 0.05% +0.033 pp | 0.00% +0.000 pp | USD2.14 -4.2% | 9 qtrs — |
| 39 | INVESCO LTD. | 32.3K -772.0 (-2.3%) | 66.1K +12.6K (+23.6%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD1.93 +6.2% | 3 qtrs — |
| 40 | PRICE T ROWE ASSOCIATES INC /MD/ | 30.6K +— (+0.0%) | 63.0K +13.0K (+26.0%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 41 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 28.9K +912.0 (+3.3%) | 59.2K +13.9K (+30.7%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 42 | CAXTON CORP | 28.5K +12.1K (+73.6%) | 58.3K +31.8K (+119.6%) | 0.03% +0.013 pp | 1.36% +1.247 pp | USD2.74 -25.2% | 5 qtrs — |
| 43 | INTECH INVESTMENT MANAGEMENT LLC | 26.9K -5.0K (-15.8%) | 55.1K +3.4K (+6.6%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD1.94 +5.7% | 3 qtrs — |
| 44 | JPMORGAN CHASE & CO | 24.8K -25.1K (-50.2%) | 50.9K -30.0K (-37.0%) | 0.03% -0.028 pp | 0.00% +0.000 pp | USD1.81 +13.3% | 3 qtrs — |
| 45 | VIRTU FINANCIAL LLC | 22.9K +9.4K (+70.1%) | 47.0K +25.0K (+113.6%) | 0.03% +0.011 pp | 0.00% +0.001 pp | USD1.80 +13.9% | 2 qtrs — |
| 46 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 21.5K -24.1K (-52.8%) | 44.1K -29.7K (-40.3%) | 0.02% -0.027 pp | 0.00% +0.000 pp | USD2.19 -6.4% | 4 qtrs — |
| 47 | XTX TOPCO LTD | 20.3K +20.3K (+100.0%) | 41.6K +41.6K (+100.0%) | 0.02% +0.023 pp | 0.00% +0.001 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 48 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 17.6K +— (+0.0%) | 36.2K +7.6K (+26.5%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 49 | SCIENTECH RESEARCH LLC | 16.0K +16.0K (+100.0%) | 32.8K +32.8K (+100.0%) | 0.02% +0.018 pp | 0.02% +0.021 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 50 | VOYA INVESTMENT MANAGEMENT LLC | 13.1K +— (+0.0%) | 26.9K +5.7K (+26.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 51 | BNP PARIBAS ARBITRAGE, SNC | 12.9K -2.7K (-17.6%) | 26.4K +1.1K (+4.3%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD1.81 +13.3% | 3 qtrs — |
| 52 | SANCTUARY ADVISORS, LLC | 12.5K +12.5K (+100.0%) | 25.7K +25.7K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 53 | VICTORY CAPITAL MANAGEMENT INC | 11.4K +11.4K (+100.0%) | 23.4K +23.4K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 54 | PROSHARE ADVISORS LLC | 11.0K +705.0 (+6.8%) | 22.6K +5.9K (+35.2%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD1.96 +4.6% | 3 qtrs — |
| 55 | RUSSELL INVESTMENTS GROUP, LTD. | 10.8K +3.1K (+40.4%) | 22.2K +9.7K (+77.7%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD1.74 +17.8% | 2 qtrs — |
| 56 | BUCKINGHAM STRATEGIC PARTNERS | 10.7K +11.0 (+0.1%) | 22.0K +4.6K (+26.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 57 | HRT FINANCIAL LP | 10.6K +10.6K (+100.0%) | 21.0K +21.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 58 | ROYAL BANK OF CANADA | 6.7K +6.0K (+903.5%) | 14.0K +13.0K (+1,300.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD2.04 +0.5% | 3 qtrs — |
| 59 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.5K -537.0 (-7.6%) | 13.3K +1.9K (+16.9%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.62 +26.5% | 3 qtrs — |
| 60 | AMERITAS INVESTMENT PARTNERS, INC. | 6.2K +— (+0.0%) | 12.7K +2.7K (+26.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 61 | LEGAL & GENERAL GROUP PLC | 5.5K +— (+0.0%) | 11.3K +2.4K (+26.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 62 | PINNACLE WEALTH PLANNING SERVICES, INC. | 5.4K +5.4K (+100.0%) | 11.1K +11.1K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD2.05 +0.0% | 1 qtrs NEW |
| 63 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 3.7K -61.0 (-1.6%) | 7.6K +1.5K (+24.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 64 | CITIGROUP INC | 3.3K +2.4K (+264.3%) | 6.7K +5.3K (+361.1%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD2.38 -13.9% | 5 qtrs — |
| 65 | STERLING CAPITAL MANAGEMENT LLC | 3.2K -607.0 (-15.9%) | 6.6K +401.0 (+6.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.75 +17.1% | 3 qtrs — |
| 66 | AMALGAMATED BANK | 1.9K -165.0 (-8.0%) | 4.0K +1.0K (+33.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.95 +5.1% | 3 qtrs — |
| 67 | PNC FINANCIAL SERVICES GROUP, INC. | 101.00 +11.0 (+12.2%) | 207.00 +61.0 (+41.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.65 +24.2% | 2 qtrs — |
| 68 | EVERSOURCE WEALTH ADVISORS, LLC | 4.00 +4.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +2.5% | 1 qtrs NEW |
| 69 | ALLWORTH FINANCIAL LP | 1.00 +1.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +2.5% | 1 qtrs NEW |
| 70 | SRS CAPITAL ADVISORS, INC. | — -86.0 (-100.0%) | — -139.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 40 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.14% | 294.1K | 0.50% |
| 2 | iShares Micro-Cap ETF IWC | 0.06% | 829.7K | 0.60% |
| 3 | iShares Russell 2000 Value ETF IWN | 0.02% | 2.23M | 0.24% |
| 4 | Vanguard Russell 2000 Value ETF VTWV | 0.01% | 130.0K | 0.06% |
| 5 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 227.5K | 0.30% |
| 6 | Global X - Russell 2000 ETF RSSL | 0.01% | 115.8K | 0.08% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 25.1K | 0.25% |
| 8 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 4.3K | 0.39% |
| 9 | iShares Russell 2000 ETF IWM | 0.01% | 6.26M | 0.19% |
| 10 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 40.8K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
6.87M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+6,869,142
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-21 | Munshi Amit | Director | D-Return | D | Common Stock | 19,089 | 0.00 | — | 38,176 | D | ↗ |
| 2026-02-21 | Cabell Christopher | Officer | D-Return | D | Common Stock | 338,282 | 0.00 | — | 676,564 | D | ↗ |
| 2026-02-21 | Aurentz Vincent | Director | D-Return | D | Common Stock | 255,299 | 0.00 | — | 510,596 | D | ↗ |
| 2026-01-05 | McIntyre David | Officer | A-Award | A | Stock Option (Right to Buy) | 986,319 | 2.01 | 1.98M | 986,319 | D | ↗ |
| 2026-01-05 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 4,982,706 | 2.01 | 10.02M | 4,982,706 | D | ↗ |
| 2026-01-05 | Cabell Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 900,117 | 2.01 | 1.81M | 900,117 | D | ↗ |
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10% Owner | P-Purchase | A | Common Stock | 2,068,965 | 1.45 | 3.00M | 13,018,965 | D | ↗ |
| 2025-06-30 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-30 | Kush Arvind | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-30 | Canner David | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-30 | Bellini Roberto | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-30 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-30 | Aurentz Vincent | Director | A-Award | A | Stock Option (Right to Buy) | 108,176 | 1.95 | 210.9K | 108,176 | D | ↗ |
| 2025-06-06 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 10,950,000 | D | ↗ |
| 2025-04-14 | McIntyre David | Officer | — | — | Common Stock | 0 | 0.00 | — | 10,285 | D | ↗ |
| 2025-02-21 | Munshi Amit | Director | A-Award | A | Common Stock | 57,265 | 0.00 | — | 57,265 | D | ↗ |
| 2025-02-21 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 602,346 | 2.23 | 1.34M | 602,346 | D | ↗ |
| 2025-02-21 | Cabell Christopher | Officer | A-Award | A | Stock Option (Right to Buy) | 1,100,705 | 2.23 | 2.45M | 1,100,705 | D | ↗ |
| 2025-02-21 | Aurentz Vincent | Director | A-Award | A | Stock Option (Right to Buy) | 134,427 | 2.23 | 299.8K | 134,427 | D | ↗ |
| 2025-02-17 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,794,291 | 2.35 | 4.22M | 1,794,291 | D | ↗ |
| 2025-02-14 | Munshi Amit | Director | A-Award | A | Stock Option (Right to Buy) | 56,600 | 2.35 | 133.0K | 56,600 | D | ↗ |
| 2025-02-14 | Kush Arvind | Director | A-Award | A | Stock Option (Right to Buy) | 56,600 | 2.35 | 133.0K | 56,600 | D | ↗ |
| 2025-02-14 | Iwicki Mark T | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 4,373,857 | 2.35 | 10.28M | 4,373,857 | D | ↗ |
| 2025-02-14 | Freeman Roy Lester | Director | A-Award | A | Stock Option (Right to Buy) | 22,640 | 2.35 | 53.2K | 22,640 | D | ↗ |
| 2025-02-14 | Canner David | Director | A-Award | A | Stock Option (Right to Buy) | 22,640 | 2.35 | 53.2K | 22,640 | D | ↗ |
| 2025-02-14 | Bellini Roberto | Director | A-Award | A | Stock Option (Right to Buy) | 73,580 | 2.35 | 172.9K | 73,580 | D | ↗ |
| 2025-02-14 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (Right to Buy) | 39,620 | 2.35 | 93.1K | 39,620 | D | ↗ |
| 2025-01-21 | Werner Milton H. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 3,643 | 1.26 | 4.6K | 3,643 | D | ↗ |
| 2025-01-21 | Lees-Rolfe Garth | Officer | A-Award | A | Stock Option (Right to Buy) | 5,834 | 1.26 | 7.4K | 5,834 | D | ↗ |
| 2025-01-21 | Freeman Roy Lester | Director | A-Award | A | Stock Option (Right to Buy) | 1,138 | 1.26 | 1.4K | 1,138 | D | ↗ |
| 2025-01-21 | BERMAN DENNIS N | Director | D-Return | D | Stock Option (Right to Buy) | 6,667 | 3.61 | 24.1K | 0 | I | ↗ |
| 2025-01-03 | Werner Milton H. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 5,315,056 | 1.26 | 6.70M | 5,315,056 | D | ↗ |
| 2025-01-03 | Lees-Rolfe Garth | Officer | A-Award | A | Stock Option (Right to Buy) | 470,861 | 1.26 | 593.3K | 470,861 | D | ↗ |
| 2025-01-03 | Freeman Roy Lester | Director | A-Award | A | Stock Option (Right to Buy) | 344,452 | 1.26 | 434.0K | 344,452 | D | ↗ |
| 2025-01-03 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (Right to Buy) | 344,452 | 1.26 | 434.0K | 344,452 | D | ↗ |
| 2024-10-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 10,950,000 | D | ↗ |
| 2024-10-21 | Munshi Amit | Director | P-Purchase | A | Common Stock | 365,000 | 1.37 | 500.1K | 365,000 | I | ↗ |
| 2024-10-21 | Kush Arvind | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-21 | Canner David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-21 | Bellini Roberto | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-16 | GRINT PAUL C | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.54 | 46.2K | 30,000 | — | ↗ |
| 2024-07-16 | Freeman Roy Lester | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.54 | 46.2K | 30,000 | — | ↗ |
| 2024-07-16 | Dion Gisele | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.54 | 46.2K | 30,000 | — | ↗ |
| 2024-07-16 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 1.54 | 46.2K | 30,000 | — | ↗ |
| 2024-04-01 | Werner Milton H. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 45,000 | 2.16 | 97.2K | 45,000 | — | ↗ |
| 2024-04-01 | Lees-Rolfe Garth | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 2.16 | 194.4K | 90,000 | — | ↗ |
| 2023-06-30 | GRINT PAUL C | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 3.61 | 24.1K | 6,667 | — | ↗ |
| 2023-06-30 | Freeman Roy Lester | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 3.61 | 24.1K | 6,667 | — | ↗ |
| 2023-06-30 | Dion Gisele | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 3.61 | 24.1K | 6,667 | — | ↗ |
| 2023-06-30 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (right to buy) | 6,667 | 3.61 | 24.1K | 6,667 | — | ↗ |
| 2023-03-01 | Werner Milton H. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 210,000 | 0.74 | 155.4K | 210,000 | — | ↗ |
| 2023-03-01 | FRATTAROLI JOSEPH | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 0.74 | 66.6K | 90,000 | — | ↗ |
| 2022-09-01 | Dion Gisele | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-08-16 | Werner Milton H. | Officer | P-Purchase | A | Common Stock | 5,000 | 0.80 | 4.0K | 5,335,433 | — | ↗ |
| 2022-06-24 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-24 | GRINT PAUL C | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.81 | 32.4K | 40,000 | — | ↗ |
| 2022-06-24 | Freeman Roy Lester | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-24 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-05-27 | Werner Milton H. | Officer | P-Purchase | A | Common Stock | 5,000 | 0.98 | 4.9K | 5,330,433 | — | ↗ |
| 2022-05-20 | Werner Milton H. | Officer | P-Purchase | A | Common Stock | 10,000 | 0.60 | 6.0K | 5,325,433 | — | ↗ |
| 2022-05-19 | FRATTAROLI JOSEPH | Officer | P-Purchase | A | Common Stock | 3,948 | 0.64 | 2.5K | 48,091 | — | ↗ |
| 2022-03-07 | Werner Milton H. | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-03-07 | FRATTAROLI JOSEPH | Officer | A-Award | A | Stock Option (right to buy) | 62,500 | 0.00 | — | 62,500 | — | ↗ |
| 2022-01-03 | Werner Milton H. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 21,853 | 2.02 | 44.1K | 5,315,433 | — | ↗ |
| 2021-11-17 | Werner Milton H. | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,334 | 1.94 | 2.6K | 23,589 | — | ↗ |
| 2021-08-25 | FRATTAROLI JOSEPH | Officer | — | I | Warrant (right to buy) | 150,000 | 5.90 | 885.0K | 0 | — | ↗ |
| 2021-08-17 | Werner Milton H. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 21,853 | 2.02 | 44.1K | 5,293,580 | — | ↗ |
| 2021-06-25 | O'Farrell Elizabeth G. | Director | A-Award | A | Stock Option (right to buy) | 22,677 | 2.92 | 66.2K | 22,677 | — | ↗ |
| 2021-06-25 | GRINT PAUL C | Director | A-Award | A | Stock Option (right to buy) | 22,677 | 2.92 | 66.2K | 22,677 | — | ↗ |
| 2021-06-25 | Freeman Roy Lester | Director | A-Award | A | Stock Option (right to buy) | 22,677 | 2.92 | 66.2K | 22,677 | — | ↗ |
| 2021-06-25 | BERMAN DENNIS N | Director | A-Award | A | Stock Option (right to buy) | 22,677 | 2.92 | 66.2K | 22,677 | — | ↗ |
| 2021-05-14 | Werner Milton H. | Director / Officer / 10% Owner | M-Exempt | A | Common Stock | 43,707 | 0.38 | 16.6K | 5,288,645 | — | ↗ |
| 2020-12-28 | FRATTAROLI JOSEPH | Officer | C-Conversion | D | Convertible Note | 0 | 10.00 | — | 0 | — | ↗ |
| 2020-12-22 | Werner Milton H. | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,244,938 | — | ↗ |
| 2020-12-22 | O'Farrell Elizabeth G. | Director | — | D | Stock Option (right to buy) | 43,707 | 5.57 | 243.4K | 0 | — | ↗ |
| 2020-12-22 | GRINT PAUL C | Director | — | D | Stock Option (right to buy) | 43,707 | 5.57 | 243.4K | 0 | — | ↗ |
| 2020-12-22 | Freeman Roy Lester | Director | — | D | Stock Option (right to buy) | 43,707 | 5.57 | 243.4K | 0 | — | ↗ |
| 2020-12-22 | FRATTAROLI JOSEPH | Officer | — | I | Convertible Note | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-22 | BERMAN DENNIS N | Director | — | I | Stock Option (right to buy) | 43,707 | 5.57 | 243.4K | 0 | — | ↗ |
| 2011-06-15 | Kalman Daniel | 10% Owner | — | D | Stock Option (right to buy) | 1,748,312 | 0.38 | 664.4K | 0 | — | ↗ |
| 2011-06-01 | Werner Milton H. | Director / Officer / 10% Owner | — | D | Stock Option (right to buy) | 43,707 | 0.38 | 16.6K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
71.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mark Iwicki Chief Executive Officer and Director | 624.2K | — | — | 29.43M | 532.5K | — | 30.59M | 96.22% | ↗ |
| 2 | 2025 | Chris Cabell, M.D. President and Head of Research and Development | 429.2K | — | — | 6.76M | 281.3K | — | 7.48M | 90.50% | ↗ |
| 3 | 2025 | David McIntyre Chief Financial Officer | 347.2K | — | — | 4.90M | 272.8K | — | 5.52M | 88.77% | ↗ |
| 4 | 2025 | Milton H. Werner, Ph.D. Former President and Chief Executive Officer | 729.0K | — | — | 40.4K | 31.5K | 2.1K | 803.1K | 5.04% | ↗ |
| 5 | 2024 | Milton H. Werner, Ph.D. Former President and Chief Executive Officer | 523.0K | — | — | 7.17M | 267.8K | 15.8K | 7.98M | 89.89% | ↗ |
| 6 | 2024 | Garth Lees-Rolfe Former Chief Financial Officer | 307.0K | — | — | 799.7K | 103.5K | — | 1.21M | 66.08% | ↗ |
| 7 | 2024 | Joseph Frattaroli, CPA Former Chief Financial Officer | 354.9K | — | — | 15.5K | — | — | 370.4K | 4.19% | ↗ |
| 8 | 2023 | Milton H. Werner, Ph.D. Former President and Chief Executive Officer | 510.0K | — | — | 113.5K | 170.9K | 17.1K | 811.4K | 13.98% | ↗ |
| 9 | 2023 | Milton H. Werner, Ph.D. President and Chief Executive Officer | 510.0K | — | — | 113.5K | 170.9K | 17.1K | 811.4K | 13.98% | ↗ |
| 10 | 2023 | Joseph Frattaroli, C.P.A. Former Chief Financial Officer | 408.3K | — | — | 48.6K | 123.0K | — | 580.0K | 8.39% | ↗ |
| 11 | 2023 | Joseph Frattaroli, CPA Former Chief Financial Officer | 408.3K | — | — | 48.6K | 123.0K | — | 580.0K | 8.39% | ↗ |
| 12 | 2022 | Milton H. Werner, Ph.D. President and Chief Executive Officer | 500.8K | — | — | 85.9K | 140.3K | 17.1K | 744.1K | 11.54% | ↗ |
| 13 | 2022 | Joseph Frattaroli, C.P.A. Former Chief Financial Officer | 395.8K | — | — | 42.9K | 136.0K | — | 574.8K | 7.47% | ↗ |
| 14 | 2022 | Joseph Frattaroli, C.P.A. Chief Financial Officer | 395.8K | — | — | 42.9K | 136.0K | — | 574.8K | 7.47% | ↗ |
| 15 | 2021 | Milton H. Werner, Ph.D. President and Chief Executive Officer | 455.0K | — | — | — | 138.5K | 17.1K | 610.7K | 0.00% | ↗ |
| 16 | 2021 | Joseph Frattaroli, C.P.A. Chief Financial Officer | 375.0K | — | — | — | 112.5K | — | 487.5K | 0.00% | ↗ |
| 17 | 2020 | Joseph Frattaroli, C.P.A. Chief Financial Officer | 300.0K | — | — | 1.34M | — | — | 1.64M | 81.73% | ↗ |
| 18 | 2020 | Milton H. Werner, Ph.D. President and Chief Executive Officer | 292.8K | — | — | 653.4K | — | 14.5K | 960.7K | 68.01% | ↗ |
| 19 | 2019 | Milton H. Werner, Ph.D. President and Chief Executive Officer | 292.8K | — | — | 77.3K | — | 14.5K | 384.6K | 20.09% | ↗ |
| 20 | 2019 | Joseph Frattaroli, C.P.A. Chief Financial Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark T. Iwicki | Chief Executive Officer & Director | 1M | male |
| Christopher H. Cabell FACC | President, Head of Research & Development and Chief Medical Officer | 782.1K | — |
| David John McIntyre | Chief Financial Officer | 668.3K | male |
| Timothy J. Pigot | Chief Commercial & Strategy Officer | — | male |
| Jeffrey J. Kagy | Chief Human Resources Officer | — | male |
| Chadwick J. Orevillo | Executive Vice President & Head of Development Operations | — | male |
| John Adams | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IKT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
